Bonesupport

The CMD will focus on the continued execution of the company’s strategy, with an increased emphasis on segment-specific initiatives to accelerate penetration and unlock the full potential of CERAMENT®.

Key highlights include:

• An upward revision of the U.S. market opportunity to approximately 460,000 procedures (from 380,000) across relevant orthopedic indications.
• Continued investment in clinical evidence, including a multicentre randomized study in arthroplasty to be initiated in 2027.
• Progression in spine with a multicentre study, planned to start in 2027 and a targeted FDA submission no later than 2031.

CEO Torbjörn Sköld and other members of the management team will present and answer questions. Two key opinion leaders (KOLs) in orthopedics, in revision arthroplasty and trauma respectively, will present their clinical experiences of CERAMENT.

The event will be held at the Helio, GT30 Grev Ture, room Bond, Grev Turegatan 30 i Stockholm. The CMD will also be broadcast live. To participate please register here: https://bonesupport.events.inderes.com/cmd-2026

The event will be available afterwards on the BONESUPPORT website.